Skip to main content

Advertisement

SpringerLink
Log in

Assessment of “squamous cell carcinoma antigen” (SCC) as a marker of epidermoid carcinoma of the anal canal

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

We measured squamous cell carcinoma antigen (SCC) in epidermoid carcinoma of the anal canal in 66 patients. Samples were taken at diagnosis, before treatment, and during follow-up; 353 samples were analyzed. The positive threshold was taken as 2 ng/ml. At diagnosis, the sensitivity of the marker was 44 percent and its specificity 92 percent. In our series, the pretherapeutic level of SCC does not correlate with T as in Papillons' Clinical Staging System, but it does correlate with nodal invasion (P<0.05). It is of no prognostic value at the time of diagnosis. During follow-up, at relapse the level of SCC is 20.3 ±43 ng/ml. This increase is significant (P<0.01); the sensitivity of the marker is 77 percent. In patients who have relapsed, development of the illness correlates with the level of SCC, which is of prognostic value (P<0.01). In conclusion, the level of SCC should be associated with the clinical follow-up of patients with epidermoid carcinoma of the anal canal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977;40:1621–8.

    PubMed  CAS  Google Scholar 

  2. Kato H, Morioka H, Aramaki S, Torigoe T. Radioimmunoassay for tumor-antigen of human cervical squamous cell carcinoma. Cell Mol Biol 1979;25:51–6.

    CAS  Google Scholar 

  3. Kato H, Miyauchi F, Morioka H, Fujino T, Torigoe T. Tumor antigen of human cervical squamous cell carcinoma: correlation of circulating levels with disease progress. Cancer 1979;43:585–90.

    PubMed  CAS  Google Scholar 

  4. Kato H, Morioka H, Tsutsui H, Aramaki S, Torigoe T. Value of tumor-antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 1982;50:1294–6.

    PubMed  CAS  Google Scholar 

  5. Kato H, Morioka H, Aramaki S, Tamai K, Torigoe T. Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix. Am J Obstet Gynecol 1983;145:350–4.

    PubMed  CAS  Google Scholar 

  6. Kato H, Tamai K, Morioka H, Nagai M, Nagaya T, Torigoe T. Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer 1984;54:1544–6.

    PubMed  CAS  Google Scholar 

  7. Maruo T, Shibata K, Kimura A, Hoshina M, Mochizuki M. Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix: serial determinations and tissue localization. Cancer 1985;56:302–8.

    PubMed  CAS  Google Scholar 

  8. Yamanaka N, Himi T, Harabuchi Y, Hoki K, Kataura A. Soluble immune complexes and squamous cell carcinoma-related antigens in patients with head and neck cancer. Cancer 1988;62:1932–8.

    PubMed  CAS  Google Scholar 

  9. Ebert W, Kayser K, Buelzebruck H, Vogt-Moykopf I. Diagnostic validity of the SCC antigen assays in squamous cell carcinoma. Tumor Marker Oncol 1988;3:35–43.

    Google Scholar 

  10. Ebert W, Stabrey A, Bulzebruck H, Kayser K, Merkle N. Efficiency of SCC antigen determinations for diagnosis and therapy-monitoring of squamous cell carcinoma of the lung. Tumor Diagn Ther 1988;9;87–95.

    Google Scholar 

  11. Sugimachi K, Kitamura M, Matsuda H, Okudaira Y. Tumor antigen TA-4: an aid in detecting post-operative recurrences of esophageal carcinoma. Dis Markers 1987;5:67–73.

    PubMed  CAS  Google Scholar 

  12. Burtin P, Daver A, Rossi V,et al. Antigène squamous cell carcinoma (SCC) au cours du suivi des patients porteurs d'un carcinome épidermoide de l'oesophage (abstr). Gastroenterol Clin Biol 1989;13:A88.

    Google Scholar 

  13. Duk J, Voorst Vader P, Hoor K, Hellema H, Doeglas H, Bruijn H. Elevated levels of squamous cell carcinoma antigen in patients with a benign disease of the skin. Cancer 1989;64:1652–6.

    PubMed  CAS  Google Scholar 

  14. Petrelli N, Shaw N, Bhargava A,et al. Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J Clin Oncol 1988;6:782–5.

    PubMed  CAS  Google Scholar 

  15. Petrelli N, Bhargaya A, Herrera L, Miller S, Shaw N. The role of squamous cell carcinoma (SCC) antigen as a tumor marker in patients with primary squamous cell carcinoma of the anal canal. Biomarkers Diagnosis Proc Assoc 1989;3.

  16. Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal: a series of 276 cases. Dis Colon Rectum 1987;30:324–33.

    PubMed  CAS  Google Scholar 

  17. World Health Organization. Normal for reporting results in cancer treatment. WHO Offset Publ No. 48 Genève, 1980.

  18. Crombach G, Wurz H, Kreienberg R,et al. Evaluation of SCC antigen as a tumor marker for cervical cancer: a cooperative study of the GTMG. Tumor Marker Oncol 1988;3:59–63.

    Google Scholar 

  19. Crombach G, Scharl A, Vierbuchen M, Wurz H, Bolte A. Detection of squamous cell carcinoma anti-gen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix. Cancer 1989;63:1337–42.

    PubMed  CAS  Google Scholar 

  20. Fuith L, Daxenbichler G. Squamous cell carcinoma antigen in patients with cancer of the uterine cervix. Gynecol Obstet Invest 1988;26:77–82.

    Article  PubMed  CAS  Google Scholar 

  21. Daver A, Dalifard I. Intérêt diagnostique du dosage du SCC-TA4 dans quatre localisations de cancers épïdermoides: expérience du sous-groupe de radioanalyse de la FNCLCC. Bull Cancer (Paris) (in press).

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Radioanalysis Laboratory, Centre Antoine-Lacassagne, Nice, France

    X. Fontana M.D., M. Sordage M.D. & F. Lapalus M.D.

  2. Department of Radiotherapy, Centre Antoine-Lacassagne, Nice, France

    J. L. Lagrange M.D. & P. Chauvel M.D.

  3. Department of Internal Medicine and Oncology, Centre Antoine-Lacassagne, Nice, France

    E. Francois M.D., J. Bourry M.D. & M. Namer M.D.

Authors
  1. X. Fontana M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. L. Lagrange M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Francois M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Bourry M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Chauvel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Sordage M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Lapalus M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Namer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Fontana, X., Lagrange, J.L., Francois, E. et al. Assessment of “squamous cell carcinoma antigen” (SCC) as a marker of epidermoid carcinoma of the anal canal. Dis Colon Rectum 34, 126–131 (1991). https://doi.org/10.1007/BF02049985

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02049985

Key words

Search

Navigation